MedTrace Logo

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

NCT01506596 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.

Conditions

  • Liposarcoma
  • Surgically Unresectable Liposarcoma
  • Metastatic Liposarcoma

Interventions

DRUG

pazopanib

Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Vector Oncology

    lead OTHER

Principal Investigators

  • Brian L Samuels, MD · Northwest Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-10-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01506596 on ClinicalTrials.gov